Invasive fungal infections have extremely high rates of morbidity and mortality, particularly in
immunocompromised hosts. Combination antifungal therapy is conceptually attractive as a …

Invasive fungal infections are major causes of mortality in immunocompromised patients.
Despite improved outcomes with new antifungals, there remains a pressing need to further …

The past decade has seen a significant increase in the incidence of invasive fungal
infections. The antifungal armamentarium for the treatment of serious fungal infections …

The incidence of invasive fungal infections has been on the rise, particularly in transplant
recipients and in patients with hematological malignancies and other forms of …

The rationale of combination antifungal therapy in severely... : Current Opinion in Infectious
Diseases The rationale of combination antifungal therapy in severely immunocompromised …

In general, mortality rates associated with systemic fungal infections have not improved
much in more than a decade, although the number of antifungal agents available for the …

Concurrent or sequential antifungal treatment for invasive mycoses has been typically
considered as an option to improve results of monotherapy. However, data on the efficacy of …

The use of antifungal combination therapy is a new clinical approach for combating fungal
infections. Although few conclusive clinical studies have been performed to date, data exist …

The cure rate for serious fungal diseases with currently available agents used as
monotherapy is not optimal. The introduction of new classes of antifungal drugs in the last …

The availability of new antifungal agents with unique mechanisms of action and improved
tolerability has widened the possibilities for the use of combination antifungal therapy for …